Segment Information (Tables)

9 Months Ended

Sep. 30, 2026

Summary of Revenue, Expenses and Net Loss for the Segment and is Reconciled to Net Loss on a Consolidated Basis

The table below highlights the Company’s revenue, expenses and net loss for the segment and is reconciled to net loss on a consolidated basis for the three and nine months ended September 30, 2026 and 2025.


	Three Months Ended						Nine Months Ended
	September 30,						September 30,
(in thousands)	2026			2025			2026			2025
Net sales	$	121,469		$	67,455		$	292,212		$	176,731

Cost of sales
Cost of goods sold (excluding depreciation and amortization) (a)	$	41,558		$	34,734		$	120,196		$	119,206
Stock-based compensation		1,721			1,408			4,276			5,977
Royalties		4,749			2,335			9,649			4,890
Total cost of sales	$	48,028		$	38,477		$	134,121		$	130,073

Expenses
Research and development	$	44,566		$	70,163		$	155,709		$	207,780
General and administrative		17,681			17,865			54,998			61,286
Sales and marketing		15,552			11,209			46,205			32,141
Depreciation and amortization		9,497			9,007			27,536			26,422
Restructuring charges		-			5,143			-			5,143
Other segment items (b)		8,416			6,844			22,274			32,960
Total expenses	$	95,712		$	120,231		$	306,722		$	365,732

Net loss	$	(22,271	)	$	(91,253	)	$	(148,631	)	$	(319,074	)

Cost of goods sold represents inventory and period costs related to overhead, manufacturing costs of Amtagvi®, and reserves associated with excess and obsolete inventory, as well as costs associated with the purchases and sales of Proleukin®. Also included are manufacturing and period costs incurred for Amtagvi® that do not meet specifications or a patient is unable to receive the infusion. For patients that can be administered Amtagvi® as part of a clinical trial in an expanded or early access program, or single-patient investigational new drug submission, costs are recorded as research and development expenses based on the fact the Company receives clinical data related to these infusions. This category is provided to the CODM on a quarterly basis in comparison to that of previous quarters for review as these costs are controllable costs that indicate operating performance of the Company.

Other segment items include costs that are not considered significant expense segments nor reviewed by the CODM on a regular basis. Such amount includes stock-based compensation expenses (excluding stock-based compensation included in cost of sales), interest income, other income and expenses, and income tax benefits.